<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01018732</url>
  </required_header>
  <id_info>
    <org_study_id>V59P6E1</org_study_id>
    <nct_id>NCT01018732</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY</brief_title>
  <official_title>A Phase 2b, Open-Label, Multi-Center Study to Evaluate the Persistence of Antibody Response and to Assess the Immune Response to a Booster Dose of MenACWY Conjugate Vaccine in Subjects Previously Vaccinated as Adolescents With Either MenACWY Conjugate Vaccine or Menomune速.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the persistence of bactericidal antibodies in adolescent
      subjects who completed study V59P6 in which they received either Novartis Meningococcal
      (MenACWY) Conjugate Vaccine or Licensed polysaccharide Men ACWY vaccine (Menomune速). The
      study will also enroll age-matched subjects who have never received any other meningococcal
      vaccine (na誰ve subjects) to serve as an additional control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Persistence of antibody response at 5 years after one dose of MenACWY or Menomune
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Serum Bactericidal Activity &gt;=8 at 5 Years After Primary Vaccination</measure>
    <time_frame>Day 1 (5 years after primary vaccination)</time_frame>
    <description>Persistence of antibody response was measured by the percentage of subjects who showed a serum bactericidal activity with human complement(hSBA) &gt;= 8 [i.e. percentage of subjects with hsBA titer &gt;=8] in previously vaccinated subjects and in age-matched meningococcal vaccine naive subjects. Sera was tested against Neisseria meningitidis serogroups A, C, W-135 and Y</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer After Booster Vaccination</measure>
    <time_frame>Day 8, Day 29 (5 years after primary vaccination)</time_frame>
    <description>Immunogenicity was measured by serum bactericidal assay with human complement (hSBA) and reported as hSBA Geometric mean titer (GMT) in previously vaccinated subjects and in age-matched meningococcal vaccine-naive subjects. Sera was tested against Neisseria meningitidis serogroups A, C, W-135 and Y</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serum Bactericidal Activity &gt;=4 at 5 Years After Primary Vaccination</measure>
    <time_frame>Day 1 (5 years after primary vaccination )</time_frame>
    <description>Persistence was measured by percentage of subjects with serum bactericidal activity with human complement (hSBA) &gt;= 4 in previously vaccinated subjects and in age-matched meningococcal vaccine naive subjects. Sera was tested against Neisseria meningitidis serogroups A, C, W-135 and Y</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer at 5 Years After Primary Vaccination</measure>
    <time_frame>Day 1 (5 years after primary vaccination )</time_frame>
    <description>Persistence was measured by serum bactericidal assay with human complement(hSBA) and expressed as hSBA GMT in previously vaccinated subjects and in age-matched meningococcal vaccine naive subjects. Sera was tested against Neisseria meningitidis serogroups A, C, W-135 and Y</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serum Bactericidal Activity &gt;=4 After Booster Vaccination</measure>
    <time_frame>Day 7, Day 28 post booster (5 years after primary vaccination)</time_frame>
    <description>Immunogenicity was measured by serum bactericidal assay with human complement (hSBA) &gt;= 4 in previously vaccinated subjects and in age-matched meningococcal vaccine naive subjects. Sera was tested against Neisseria meningitidis serogroups A, C, W-135 and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serum Bactericidal Activity &gt;=8 After Booster Vaccination</measure>
    <time_frame>Day 7, Day 28 post booster (5 years after primary vaccination)</time_frame>
    <description>Immunogenicity was measured by serum bactericidal assay with human complement (hSBA) &gt;= 8 in previously vaccinated subjects and in age-matched meningococcal vaccine naive subjects. Sera was tested against Neisseria meningitidis serogroups A, C, W-135 and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio After Booster Vaccination</measure>
    <time_frame>Day 8 and Day 29 (at 5 Years After Primary Vaccination)</time_frame>
    <description>Ratios are expressed as geometric mean titer at Day 8: Day 1 and at Day 29:Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA Seroresponse After Booster Vaccination</measure>
    <time_frame>Day 8, Day 29 (5 years after primary vaccination)</time_frame>
    <description>For a subject with hSBA titer &lt;4 at baseline, seroresponse is defined as a postvaccination hSBA titer &gt;=8; and for a subject with hSBA titer &gt;=4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline. Sera was tested against Neisseria meningitidis serogroups A, C, W-135 and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With at Least One Reactogenicity Sign After Booster Vaccination</measure>
    <time_frame>Up to Day 7</time_frame>
    <description>Local and systemic reactions were solicited to assess safety and tolerability of vaccination</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">155</enrollment>
  <condition>Meningococcal Disease</condition>
  <condition>Meningococcal Meningitis</condition>
  <arm_group>
    <arm_group_label>I: MenACWY-CRM vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects had been given one dose of Meningococcal ACWY (MenACWY) vaccine conjugated to CRM197 (cross-reactive material-mutant of diptheria toxin) 5 years ago. All subjects were given one dose of the Men ACWY in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II: Licensed Polysaccharide Meningococcal vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects had been given one dose of a licensed MenACWY polysaccharide meningococcal vaccine (Menomune) 5 years ago. All subjects were given one dose of Men ACWY vaccine in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>III: Meningococcal Naive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were age matched with groups 1 and 2 (age inclusive: 16 years to 23 years) and enrolled at visit 1 and given one dose of Men ACWY vaccine during the present study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Novartis Meningococcal (MenACWY-CRM) vaccine</intervention_name>
    <description>All subjects will have blood draws at Day 1, Day 8, and Day 29.</description>
    <arm_group_label>I: MenACWY-CRM vaccine</arm_group_label>
    <arm_group_label>II: Licensed Polysaccharide Meningococcal vaccine</arm_group_label>
    <arm_group_label>III: Meningococcal Naive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adolescents or adults (age 16-23 years inclusive), either previously enrolled
             in the parent study or na誰ve to meningococcal vaccination.

          -  Female subjects were to be negative for pregnancy

        Exclusion Criteria:

          -  History of meningococcal disease

          -  Receipt of any meningococcal vaccine outside of parent study (V59P6)

          -  Serious, acute, or chronic illnesses including HIV infection/disease and any
             malignancy

          -  receipt of any vaccine 14 days prior to the study, or expected through the duration of
             the study

          -  any condition which in the eyes of the investigator would pose a health risk to the
             subject or render them inappropriate for a research study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>23 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol. 2011 Mar;18(3):483-6. doi: 10.1128/CVI.00304-10. Epub 2010 Dec 22.</citation>
    <PMID>21177912</PMID>
  </results_reference>
  <results_reference>
    <citation>Jacobson RM, Jackson LA, Reisinger K, Izu A, Odrljin T, Dull PM. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents. Pediatr Infect Dis J. 2013 Apr;32(4):e170-7. doi: 10.1097/INF.0b013e318279ac38.</citation>
    <PMID>23114372</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2009</study_first_submitted>
  <study_first_submitted_qc>November 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <results_first_submitted>August 9, 2011</results_first_submitted>
  <results_first_submitted_qc>August 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 13, 2011</results_first_posted>
  <last_update_submitted>July 14, 2015</last_update_submitted>
  <last_update_submitted_qc>July 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal</keyword>
  <keyword>ACWY</keyword>
  <keyword>Conjugate Vaccine</keyword>
  <keyword>Meningitis</keyword>
  <keyword>Adolescents</keyword>
  <keyword>Persistence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningococcal Infections</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 3 centers in the USA</recruitment_details>
      <pre_assignment_details>All subjects enrolled were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>I: MenACWY-CRM Vaccine</title>
          <description>Subjects had been given one dose of Meningococcal ACWY (MenACWY)vaccine conjugated to CRM197 (cross-reactive material-mutant of diptheria toxin) 5 years ago</description>
        </group>
        <group group_id="P2">
          <title>II: Licensed Polysaccharide Meningococcal Vaccine</title>
          <description>Subjects had been given one dose of licensed Meningococcal (Men ACWY) polysaccharide vaccine (Menomune) 5 years ago</description>
        </group>
        <group group_id="P3">
          <title>III: Meningococcal Naive</title>
          <description>Subjects were between 16 years to 23 years (age-inclusive)and meningococcal vaccine naive</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate Enrollment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to Classify</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>I: MenACWY-CRM Vaccine</title>
          <description>Subjects had been given one dose of Meningococcal ACWY (MenACWY)vaccine conjugated to CRM197 (cross-reactive material-mutant of diptheria toxin) 5 years ago</description>
        </group>
        <group group_id="B2">
          <title>II: Licensed Polysaccharide Meningococcal Vaccine</title>
          <description>Subjects had been given one dose of licensed Meningococcal (Men ACWY) polysaccharide vaccine (Menomune) 5 years ago</description>
        </group>
        <group group_id="B3">
          <title>III: Meningococcal Naive</title>
          <description>Subjects were between 16 years to 23 years (age-inclusive)and meningococcal vaccine naive</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="54"/>
            <count group_id="B4" value="155"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.8" spread="1.9"/>
                    <measurement group_id="B2" value="19.2" spread="2.0"/>
                    <measurement group_id="B3" value="20.5" spread="2.3"/>
                    <measurement group_id="B4" value="19.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Serum Bactericidal Activity &gt;=8 at 5 Years After Primary Vaccination</title>
        <description>Persistence of antibody response was measured by the percentage of subjects who showed a serum bactericidal activity with human complement(hSBA) &gt;= 8 [i.e. percentage of subjects with hsBA titer &gt;=8] in previously vaccinated subjects and in age-matched meningococcal vaccine naive subjects. Sera was tested against Neisseria meningitidis serogroups A, C, W-135 and Y</description>
        <time_frame>Day 1 (5 years after primary vaccination)</time_frame>
        <population>Full analysis set (all subjects who had no major protocol violation as defined prior to database lock).</population>
        <group_list>
          <group group_id="O1">
            <title>I:MenACWY</title>
            <description>Subjects had been given one dose of Meningococcal (MenACWY) vaccine 5 years ago and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
          <group group_id="O2">
            <title>II:Licensed Polysacharide Meningococcal Vaccine</title>
            <description>Subjects had been given one dose of licensed polysaccharide meningococcal Serogroup ACWY vaccine(Menomune),5 years ago and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
          <group group_id="O3">
            <title>III: Meningococcal-naive</title>
            <description>Subjects were meningococcal vaccine naive and age inclusive (16-23 years)and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Bactericidal Activity &gt;=8 at 5 Years After Primary Vaccination</title>
          <description>Persistence of antibody response was measured by the percentage of subjects who showed a serum bactericidal activity with human complement(hSBA) &gt;= 8 [i.e. percentage of subjects with hsBA titer &gt;=8] in previously vaccinated subjects and in age-matched meningococcal vaccine naive subjects. Sera was tested against Neisseria meningitidis serogroups A, C, W-135 and Y</description>
          <population>Full analysis set (all subjects who had no major protocol violation as defined prior to database lock).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="18" upper_limit="45"/>
                    <measurement group_id="O2" value="44" lower_limit="30" upper_limit="59"/>
                    <measurement group_id="O3" value="11" lower_limit="4" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="62" upper_limit="87"/>
                    <measurement group_id="O2" value="62" lower_limit="47" upper_limit="75"/>
                    <measurement group_id="O3" value="51" lower_limit="37" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="58" upper_limit="84"/>
                    <measurement group_id="O2" value="56" lower_limit="41" upper_limit="70"/>
                    <measurement group_id="O3" value="51" lower_limit="37" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="62" upper_limit="87"/>
                    <measurement group_id="O2" value="50" lower_limit="36" upper_limit="64"/>
                    <measurement group_id="O3" value="55" lower_limit="40" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer After Booster Vaccination</title>
        <description>Immunogenicity was measured by serum bactericidal assay with human complement (hSBA) and reported as hSBA Geometric mean titer (GMT) in previously vaccinated subjects and in age-matched meningococcal vaccine-naive subjects. Sera was tested against Neisseria meningitidis serogroups A, C, W-135 and Y</description>
        <time_frame>Day 8, Day 29 (5 years after primary vaccination)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>I:MenACWY</title>
            <description>Subjects had been given one dose of Meningococcal (MenACWY) vaccine 5 years ago and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
          <group group_id="O2">
            <title>II:Licensed Polysacharide Meningococcal Vaccine</title>
            <description>Subjects had been given one dose of licensed polysaccharide meningococcal Serogroup ACWY vaccine(Menomune),5 years ago and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
          <group group_id="O3">
            <title>III: Meningococcal-naive</title>
            <description>Subjects were meningococcal vaccine naive and age inclusive (16-23 years)and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer After Booster Vaccination</title>
          <description>Immunogenicity was measured by serum bactericidal assay with human complement (hSBA) and reported as hSBA Geometric mean titer (GMT) in previously vaccinated subjects and in age-matched meningococcal vaccine-naive subjects. Sera was tested against Neisseria meningitidis serogroups A, C, W-135 and Y</description>
          <population>Full analysis set</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, Men A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.16" lower_limit="3.46" upper_limit="7.7"/>
                    <measurement group_id="O2" value="7.31" lower_limit="4.94" upper_limit="11"/>
                    <measurement group_id="O3" value="3.06" lower_limit="2.06" upper_limit="4.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, Men A,</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1059" lower_limit="585" upper_limit="1917"/>
                    <measurement group_id="O2" value="45" lower_limit="25" upper_limit="80"/>
                    <measurement group_id="O3" value="34" lower_limit="19" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29, Men A, (N=48, G I)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="819" lower_limit="514" upper_limit="1305"/>
                    <measurement group_id="O2" value="147" lower_limit="94" upper_limit="232"/>
                    <measurement group_id="O3" value="113" lower_limit="72" upper_limit="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Men C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="13" upper_limit="33"/>
                    <measurement group_id="O2" value="19" lower_limit="12" upper_limit="31"/>
                    <measurement group_id="O3" value="7.34" lower_limit="4.6" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, Men C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1603" lower_limit="893" upper_limit="2877"/>
                    <measurement group_id="O2" value="36" lower_limit="20" upper_limit="64"/>
                    <measurement group_id="O3" value="70" lower_limit="39" upper_limit="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29, Men C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1217" lower_limit="717" upper_limit="2066"/>
                    <measurement group_id="O2" value="51" lower_limit="30" upper_limit="86"/>
                    <measurement group_id="O3" value="127" lower_limit="75" upper_limit="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Men W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="17" upper_limit="49"/>
                    <measurement group_id="O2" value="12" lower_limit="7.02" upper_limit="19"/>
                    <measurement group_id="O3" value="11" lower_limit="6.31" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, Men W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1685" lower_limit="1042" upper_limit="2725"/>
                    <measurement group_id="O2" value="34" lower_limit="21" upper_limit="54"/>
                    <measurement group_id="O3" value="63" lower_limit="39" upper_limit="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29, Men W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1644" lower_limit="1090" upper_limit="2481"/>
                    <measurement group_id="O2" value="47" lower_limit="32" upper_limit="71"/>
                    <measurement group_id="O3" value="79" lower_limit="52" upper_limit="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Men Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="18" upper_limit="45"/>
                    <measurement group_id="O2" value="7.8" lower_limit="4.91" upper_limit="12"/>
                    <measurement group_id="O3" value="8.69" lower_limit="5.45" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, Men Y, (N=48, GI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2561" lower_limit="1526" upper_limit="4298"/>
                    <measurement group_id="O2" value="21" lower_limit="13" upper_limit="35"/>
                    <measurement group_id="O3" value="64" lower_limit="39" upper_limit="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29, Men Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2092" lower_limit="1340" upper_limit="3268"/>
                    <measurement group_id="O2" value="63" lower_limit="41" upper_limit="98"/>
                    <measurement group_id="O3" value="110" lower_limit="70" upper_limit="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1, Men A, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>2.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.39</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1, Men A, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1, Men A, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>1.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 8, Men A, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>2.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 8, Men A, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11</ci_lower_limit>
            <ci_upper_limit>52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 8, Men A, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14</ci_lower_limit>
            <ci_upper_limit>69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 29, Men A, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>2.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 29, Men A, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>5.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.01</ci_lower_limit>
            <ci_upper_limit>10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 29, Men A, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>7.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.86</ci_lower_limit>
            <ci_upper_limit>13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1, Men C, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>2.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4</ci_lower_limit>
            <ci_upper_limit>4.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1, Men C, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1, Men C, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>2.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.47</ci_lower_limit>
            <ci_upper_limit>5.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 8, Men C, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.23</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 8, Men C, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21</ci_lower_limit>
            <ci_upper_limit>97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 8, Men C, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10</ci_lower_limit>
            <ci_upper_limit>51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 29, Men C, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 29, Men C, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12</ci_lower_limit>
            <ci_upper_limit>48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 29, Men C, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>9.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.69</ci_lower_limit>
            <ci_upper_limit>20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1, Men W-135, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>2.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1, Men W-135, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>2.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.27</ci_lower_limit>
            <ci_upper_limit>4.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1, Men W-135, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>2.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.38</ci_lower_limit>
            <ci_upper_limit>5.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 8, Men W-135, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 8, Men W-135, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>26</ci_lower_limit>
            <ci_upper_limit>94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 8, Men W-135, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14</ci_lower_limit>
            <ci_upper_limit>52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 29, Men W-135, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 29, Men W-135, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20</ci_lower_limit>
            <ci_upper_limit>60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 29, Men W-135, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12</ci_lower_limit>
            <ci_upper_limit>36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1, Men Y, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>1.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1, Men Y, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>3.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.94</ci_lower_limit>
            <ci_upper_limit>6.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 1, Men Y, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>3.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.71</ci_lower_limit>
            <ci_upper_limit>6.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 8, Men Y, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>0.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 8, Men Y, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>121</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>61</ci_lower_limit>
            <ci_upper_limit>241</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 8, Men Y, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20</ci_lower_limit>
            <ci_upper_limit>80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 29, Men Y, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 29, Men Y, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18</ci_lower_limit>
            <ci_upper_limit>60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 29, Men Y, Pairwise comparison of geometric mean titer</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>ratio of titer</param_type>
            <param_value>19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10</ci_lower_limit>
            <ci_upper_limit>35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serum Bactericidal Activity &gt;=4 at 5 Years After Primary Vaccination</title>
        <description>Persistence was measured by percentage of subjects with serum bactericidal activity with human complement (hSBA) &gt;= 4 in previously vaccinated subjects and in age-matched meningococcal vaccine naive subjects. Sera was tested against Neisseria meningitidis serogroups A, C, W-135 and Y</description>
        <time_frame>Day 1 (5 years after primary vaccination )</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>I:MenACWY</title>
            <description>Subjects had been given one dose of Meningococcal (MenACWY) vaccine 5 years ago and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
          <group group_id="O2">
            <title>II:Licensed Polysacharide Meningococcal Vaccine</title>
            <description>Subjects had been given one dose of licensed polysaccharide meningococcal Serogroup ACWY vaccine(Menomune),5 years ago and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
          <group group_id="O3">
            <title>III: Meningococcal-naive</title>
            <description>Subjects were meningococcal vaccine naive and age inclusive (16-23 years)and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Bactericidal Activity &gt;=4 at 5 Years After Primary Vaccination</title>
          <description>Persistence was measured by percentage of subjects with serum bactericidal activity with human complement (hSBA) &gt;= 4 in previously vaccinated subjects and in age-matched meningococcal vaccine naive subjects. Sera was tested against Neisseria meningitidis serogroups A, C, W-135 and Y</description>
          <population>Full analysis set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="21" upper_limit="49"/>
                    <measurement group_id="O2" value="50" lower_limit="36" upper_limit="64"/>
                    <measurement group_id="O3" value="23" lower_limit="12" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="71" upper_limit="93"/>
                    <measurement group_id="O2" value="68" lower_limit="53" upper_limit="80"/>
                    <measurement group_id="O3" value="70" lower_limit="56" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="66" upper_limit="90"/>
                    <measurement group_id="O2" value="58" lower_limit="43" upper_limit="72"/>
                    <measurement group_id="O3" value="55" lower_limit="40" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="62" upper_limit="87"/>
                    <measurement group_id="O2" value="60" lower_limit="45" upper_limit="74"/>
                    <measurement group_id="O3" value="60" lower_limit="46" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer at 5 Years After Primary Vaccination</title>
        <description>Persistence was measured by serum bactericidal assay with human complement(hSBA) and expressed as hSBA GMT in previously vaccinated subjects and in age-matched meningococcal vaccine naive subjects. Sera was tested against Neisseria meningitidis serogroups A, C, W-135 and Y</description>
        <time_frame>Day 1 (5 years after primary vaccination )</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>I:MenACWY</title>
            <description>Subjects had been given one dose of Meningococcal (MenACWY) vaccine 5 years ago and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
          <group group_id="O2">
            <title>II:Licensed Polysacharide Meningococcal Vaccine</title>
            <description>Subjects had been given one dose of licensed polysaccharide meningococcal Serogroup ACWY vaccine(Menomune),5 years ago and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
          <group group_id="O3">
            <title>III: Meningococcal-naive</title>
            <description>Subjects were meningococcal vaccine naive and age inclusive (16-23 years)and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer at 5 Years After Primary Vaccination</title>
          <description>Persistence was measured by serum bactericidal assay with human complement(hSBA) and expressed as hSBA GMT in previously vaccinated subjects and in age-matched meningococcal vaccine naive subjects. Sera was tested against Neisseria meningitidis serogroups A, C, W-135 and Y</description>
          <population>Full analysis set</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.21" lower_limit="3.51" upper_limit="7.74"/>
                    <measurement group_id="O2" value="7.56" lower_limit="5.12" upper_limit="11"/>
                    <measurement group_id="O3" value="3" lower_limit="2.05" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="12" upper_limit="31"/>
                    <measurement group_id="O2" value="19" lower_limit="12" upper_limit="30"/>
                    <measurement group_id="O3" value="7.62" lower_limit="4.86" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="17" upper_limit="46"/>
                    <measurement group_id="O2" value="12" lower_limit="7.17" upper_limit="20"/>
                    <measurement group_id="O3" value="11" lower_limit="6.53" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="17" upper_limit="43"/>
                    <measurement group_id="O2" value="7.67" lower_limit="4.85" upper_limit="12"/>
                    <measurement group_id="O3" value="9.38" lower_limit="5.98" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serum Bactericidal Activity &gt;=4 After Booster Vaccination</title>
        <description>Immunogenicity was measured by serum bactericidal assay with human complement (hSBA) &gt;= 4 in previously vaccinated subjects and in age-matched meningococcal vaccine naive subjects. Sera was tested against Neisseria meningitidis serogroups A, C, W-135 and Y.</description>
        <time_frame>Day 7, Day 28 post booster (5 years after primary vaccination)</time_frame>
        <population>Full Analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>I:MenACWY</title>
            <description>Subjects had been given one dose of Meningococcal (MenACWY) vaccine 5 years ago and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
          <group group_id="O2">
            <title>II:Licensed Polysacharide Meningococcal Vaccine</title>
            <description>Subjects had been given one dose of licensed polysaccharide meningococcal Serogroup ACWY vaccine(Menomune),5 years ago and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
          <group group_id="O3">
            <title>III: Meningococcal-naive</title>
            <description>Subjects were meningococcal vaccine naive and age inclusive (16-23 years)and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Bactericidal Activity &gt;=4 After Booster Vaccination</title>
          <description>Immunogenicity was measured by serum bactericidal assay with human complement (hSBA) &gt;= 4 in previously vaccinated subjects and in age-matched meningococcal vaccine naive subjects. Sera was tested against Neisseria meningitidis serogroups A, C, W-135 and Y.</description>
          <population>Full Analysis set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7 post booster, Men A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O2" value="76" lower_limit="61" upper_limit="87"/>
                    <measurement group_id="O3" value="66" lower_limit="51" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 post booster, Men A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="89" upper_limit="100"/>
                    <measurement group_id="O2" value="94" lower_limit="83" upper_limit="99"/>
                    <measurement group_id="O3" value="92" lower_limit="81" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 post booster, Men C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O2" value="82" lower_limit="68" upper_limit="91"/>
                    <measurement group_id="O3" value="94" lower_limit="83" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 post booster, Men C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O2" value="90" lower_limit="78" upper_limit="97"/>
                    <measurement group_id="O3" value="98" lower_limit="89" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 post booster, Men W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O2" value="86" lower_limit="73" upper_limit="94"/>
                    <measurement group_id="O3" value="92" lower_limit="81" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 post booster, Men W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O2" value="94" lower_limit="83" upper_limit="99"/>
                    <measurement group_id="O3" value="94" lower_limit="83" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 post booster, Men Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="89" upper_limit="100"/>
                    <measurement group_id="O2" value="78" lower_limit="63" upper_limit="88"/>
                    <measurement group_id="O3" value="92" lower_limit="81" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 post booster, Men Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="93" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serum Bactericidal Activity &gt;=8 After Booster Vaccination</title>
        <description>Immunogenicity was measured by serum bactericidal assay with human complement (hSBA) &gt;= 8 in previously vaccinated subjects and in age-matched meningococcal vaccine naive subjects. Sera was tested against Neisseria meningitidis serogroups A, C, W-135 and Y.</description>
        <time_frame>Day 7, Day 28 post booster (5 years after primary vaccination)</time_frame>
        <population>Full Analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>I:MenACWY</title>
            <description>Subjects had been given one dose of Meningococcal (MenACWY) vaccine 5 years ago and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
          <group group_id="O2">
            <title>II:Licensed Polysacharide Meningococcal Vaccine</title>
            <description>Subjects had been given one dose of licensed polysaccharide meningococcal Serogroup ACWY vaccine(Menomune),5 years ago and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
          <group group_id="O3">
            <title>III: Meningococcal-naive</title>
            <description>Subjects were meningococcal vaccine naive and age inclusive (16-23 years)and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Bactericidal Activity &gt;=8 After Booster Vaccination</title>
          <description>Immunogenicity was measured by serum bactericidal assay with human complement (hSBA) &gt;= 8 in previously vaccinated subjects and in age-matched meningococcal vaccine naive subjects. Sera was tested against Neisseria meningitidis serogroups A, C, W-135 and Y.</description>
          <population>Full Analysis set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7 post booster, Men A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O2" value="73" lower_limit="59" upper_limit="85"/>
                    <measurement group_id="O3" value="64" lower_limit="49" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 post booster, Men A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="89" upper_limit="100"/>
                    <measurement group_id="O2" value="94" lower_limit="83" upper_limit="99"/>
                    <measurement group_id="O3" value="92" lower_limit="81" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 post booster, Men C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O2" value="78" lower_limit="63" upper_limit="88"/>
                    <measurement group_id="O3" value="90" lower_limit="78" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 post booster, Men C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O2" value="84" lower_limit="70" upper_limit="93"/>
                    <measurement group_id="O3" value="98" lower_limit="89" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 post booster, Men W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O2" value="84" lower_limit="70" upper_limit="93"/>
                    <measurement group_id="O3" value="88" lower_limit="76" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 post booster, Men W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O2" value="92" lower_limit="80" upper_limit="98"/>
                    <measurement group_id="O3" value="94" lower_limit="83" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 post booster, Men Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="89" upper_limit="100"/>
                    <measurement group_id="O2" value="76" lower_limit="61" upper_limit="87"/>
                    <measurement group_id="O3" value="90" lower_limit="78" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 post booster, Men Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O2" value="96" lower_limit="86" upper_limit="100"/>
                    <measurement group_id="O3" value="98" lower_limit="89" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratio After Booster Vaccination</title>
        <description>Ratios are expressed as geometric mean titer at Day 8: Day 1 and at Day 29:Day 1</description>
        <time_frame>Day 8 and Day 29 (at 5 Years After Primary Vaccination)</time_frame>
        <population>full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>I:MenACWY</title>
            <description>Subjects had been given one dose of Meningococcal (MenACWY) vaccine 5 years ago and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
          <group group_id="O2">
            <title>II:Licensed Polysacharide Meningococcal Vaccine</title>
            <description>Subjects had been given one dose of licensed polysaccharide meningococcal Serogroup ACWY vaccine(Menomune),5 years ago and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
          <group group_id="O3">
            <title>III: Meningococcal-naive</title>
            <description>Subjects were meningococcal vaccine naive and age inclusive (16-23 years)and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio After Booster Vaccination</title>
          <description>Ratios are expressed as geometric mean titer at Day 8: Day 1 and at Day 29:Day 1</description>
          <population>full analysis set</population>
          <units>Geometric mean ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A (Day 8:1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205" lower_limit="113" upper_limit="373"/>
                    <measurement group_id="O2" value="6.1" lower_limit="3.4" upper_limit="11"/>
                    <measurement group_id="O3" value="11" lower_limit="6.17" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A (Day 29:1), N=48, N=49, N=50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155" lower_limit="92" upper_limit="262"/>
                    <measurement group_id="O2" value="20" lower_limit="12" upper_limit="33"/>
                    <measurement group_id="O3" value="37" lower_limit="22" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (Day 8:1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="47" upper_limit="130"/>
                    <measurement group_id="O2" value="1.85" lower_limit="1.13" upper_limit="3.03"/>
                    <measurement group_id="O3" value="9.48" lower_limit="5.76" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C (Day 29:1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="37" upper_limit="97"/>
                    <measurement group_id="O2" value="2.64" lower_limit="1.64" upper_limit="4.24"/>
                    <measurement group_id="O3" value="17" lower_limit="11" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W-135 (Day 8:1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="34" upper_limit="97"/>
                    <measurement group_id="O2" value="2.92" lower_limit="1.75" upper_limit="4.87"/>
                    <measurement group_id="O3" value="5.95" lower_limit="3.55" upper_limit="9.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W-135 (Day 29:1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="33" upper_limit="95"/>
                    <measurement group_id="O2" value="4.06" lower_limit="2.43" upper_limit="6.77"/>
                    <measurement group_id="O3" value="7.48" lower_limit="4.46" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (Day 8:1), N=48, N=49, N=50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="56" upper_limit="167"/>
                    <measurement group_id="O2" value="2.69" lower_limit="1.58" upper_limit="4.58"/>
                    <measurement group_id="O3" value="7.29" lower_limit="4.26" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y (Day 29:1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="43" upper_limit="129"/>
                    <measurement group_id="O2" value="8.12" lower_limit="4.73" upper_limit="14"/>
                    <measurement group_id="O3" value="13" lower_limit="7.3" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA Seroresponse After Booster Vaccination</title>
        <description>For a subject with hSBA titer &lt;4 at baseline, seroresponse is defined as a postvaccination hSBA titer &gt;=8; and for a subject with hSBA titer &gt;=4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline. Sera was tested against Neisseria meningitidis serogroups A, C, W-135 and Y.</description>
        <time_frame>Day 8, Day 29 (5 years after primary vaccination)</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>I:MenACWY</title>
            <description>Subjects had been given one dose of Meningococcal (MenACWY) vaccine 5 years ago and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
          <group group_id="O2">
            <title>II:Licensed Polysacharide Meningococcal Vaccine</title>
            <description>Subjects had been given one dose of licensed polysaccharide meningococcal Serogroup ACWY vaccine(Menomune),5 years ago and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
          <group group_id="O3">
            <title>III: Meningococcal-naive</title>
            <description>Subjects were meningococcal vaccine naive and age inclusive (16-23 years)and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA Seroresponse After Booster Vaccination</title>
          <description>For a subject with hSBA titer &lt;4 at baseline, seroresponse is defined as a postvaccination hSBA titer &gt;=8; and for a subject with hSBA titer &gt;=4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline. Sera was tested against Neisseria meningitidis serogroups A, C, W-135 and Y.</description>
          <population>Full analysis set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men A, Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O2" value="51" lower_limit="36" upper_limit="66"/>
                    <measurement group_id="O3" value="60" lower_limit="45" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men A, Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="93" upper_limit="100"/>
                    <measurement group_id="O2" value="76" lower_limit="61" upper_limit="87"/>
                    <measurement group_id="O3" value="90" lower_limit="78" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C, Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="86" upper_limit="100"/>
                    <measurement group_id="O2" value="16" lower_limit="7" upper_limit="30"/>
                    <measurement group_id="O3" value="62" lower_limit="47" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men C, Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="86" upper_limit="100"/>
                    <measurement group_id="O2" value="31" lower_limit="18" upper_limit="45"/>
                    <measurement group_id="O3" value="80" lower_limit="66" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W-135, Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="86" upper_limit="100"/>
                    <measurement group_id="O2" value="37" lower_limit="23" upper_limit="52"/>
                    <measurement group_id="O3" value="48" lower_limit="34" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men W-135, Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="89" upper_limit="100"/>
                    <measurement group_id="O2" value="47" lower_limit="33" upper_limit="62"/>
                    <measurement group_id="O3" value="58" lower_limit="43" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y, Day 8, (N=48, G I)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="83" upper_limit="99"/>
                    <measurement group_id="O2" value="33" lower_limit="20" upper_limit="48"/>
                    <measurement group_id="O3" value="54" lower_limit="39" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Men Y, Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="83" upper_limit="99"/>
                    <measurement group_id="O2" value="55" lower_limit="40" upper_limit="69"/>
                    <measurement group_id="O3" value="76" lower_limit="62" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With at Least One Reactogenicity Sign After Booster Vaccination</title>
        <description>Local and systemic reactions were solicited to assess safety and tolerability of vaccination</description>
        <time_frame>Up to Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>I:MenACWY</title>
            <description>Subjects had been given one dose of Meningococcal (MenACWY) vaccine 5 years ago and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
          <group group_id="O2">
            <title>II:Licensed Polysacharide Meningococcal Vaccine</title>
            <description>Subjects had been given one dose of licensed polysaccharide meningococcal Serogroup ACWY vaccine(Menomune),5 years ago and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
          <group group_id="O3">
            <title>III: Meningococcal-naive</title>
            <description>Subjects were meningococcal vaccine naive and age inclusive (16-23 years)and were given one dose of Men ACWY-CRM vaccine during the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Reactogenicity Sign After Booster Vaccination</title>
          <description>Local and systemic reactions were solicited to assess safety and tolerability of vaccination</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local Reactions (any-total)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (any)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (any)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (any)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sytemic Reactions (any-total)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (any)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (any)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (any)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (any)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthalgia (any)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (any)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;= 38C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed at home</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic antipyretic medication used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>safety was assessed up to 28 days after vaccination.</time_frame>
      <desc>All the AEs reported were solicited post-injection reactions</desc>
      <group_list>
        <group group_id="E1">
          <title>I: MenACWY-CRM Vaccine</title>
          <description>Subjects had been given one dose of Meningococcal ACWY (MenACWY)vaccine conjugated to CRM197 (cross-reactive material-mutant of diptheria toxin) 5 years ago</description>
        </group>
        <group group_id="E2">
          <title>II: Licensed Polysaccharide Meningococcal Vaccine</title>
          <description>Subjects had been given one dose of licensed Meningococcal (Men ACWY) polysaccharide vaccine (Menomune) 5 years ago</description>
        </group>
        <group group_id="E3">
          <title>III: Meningococcal Naive</title>
          <description>Subjects were between 16 years to 23 years (age-inclusive)and meningococcal vaccine naive</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="50"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="50"/>
                <counts group_id="E3" events="33" subjects_affected="33" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="50"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="50"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="50"/>
                <counts group_id="E3" events="31" subjects_affected="31" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

